🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Info Edge-backed Truemeds' gross revenue crosses Rs 300 Cr in FY24

EntrackrEntrackr · 5m ago
Info Edge-backed Truemeds' gross revenue crosses Rs 300 Cr in FY24
Medial

Telehealth platform Truemeds saw rapid growth, surpassing Rs 300 crore in gross revenue for the fiscal year ending March 2024. The Mumbai-based company also reduced its losses by 9% during the same period. Truemeds’ gross revenue surged 2X to Rs 315 crore in FY24 from Rs 154 crore in FY23, according to its annual financial statements filed with the Registrar of Companies (RoC). Founded by Akshat Nayyar and Kunal Wani, the startup enables consumers to discover alternative brand medicines by uploading their prescriptions. Revenue from medicine and medical device sales accounted for 98.4% of the total operating income, which surged 102% to Rs 310 crore in FY24. Income from shipping and packaging stood at Rs 1.7 crore and Rs 2.8 crore respectively. The company also added Rs 10 crore from interest on deposits which tallied its overall income to Rs 325 crore in FY24 from Rs 161 crore in FY23. As a telehealth platform, the cost of procuring medicines and devices accounted for 67.8% of the total expenditure. With increasing scale, this cost rose by 96% to Rs 262 crore in FY24. Employee benefits also grew by 75% to Rs 42 crore in FY24. Its advertising, rent, information technology, legal, and other overheads took the overall cost up by 74.7% to Rs 386 crore in FY24 from Rs 221 crore in FY23. The two-fold growth and controlled expenditure helped Truemeds to reduce its losses by 9% to Rs 61 crore in FY24, compared to Rs 67 crore in FY23. On a unit level, it spent Rs 1.23 to earn a rupee in FY24. Truemeds’ ROCE and EBITDA margin improved to -27.6% and -18.15% respectively. At the end of FY24, its total current assets stood at Rs 253 crore with cash and bank balances of Rs 155 crore. Truemeds has secured over $27 million in funding to date, including a $22 million Series B round led by WestBridge Capital in 2022. As per startup data intelligence platform TheKredible, Info Edge is the largest external stakeholder, holding a 25.25% stake in the company. PharmEasy, Tata 1mg, Netmeds, and Apollo 247 are among Truemeds' direct competitors. An easy to use interface, and a real demand for reducing medical costs has provided a strong opening for many firms in the space.

Related News

Info Edge crosses Rs 2,500 Cr revenue and Rs 500 Cr profit threshold in FY24

EntrackrEntrackr · 1y ago
Info Edge crosses Rs 2,500 Cr revenue and Rs 500 Cr profit threshold in FY24
Medial

Info Edge, the parent company of Naukri and 99acres, published its financial statements on Thursday. The consolidated figures showcased a modest 8% increase in revenue for FY24. However, the company made a turnaround in its bottom line, transitioning from a loss of Rs 70 crore in FY23 to a profit of Rs 594 crore in FY24. Info Edge’s revenue from operations grew 8% to Rs 2,536 crore in FY24 from Rs 2,345 crore in FY23, its consolidated financial statements disclosed with the stock exchange shows. Meanwhile, the company posted a 4.8% increase in revenue to Rs 657 crore in Q4 FY24 from Rs 627 crore in Q3 FY24. The Sanjeev Bikchandani-led firm operates through different segments. Income from Naukari.com and related portals formed 74.1% of its total revenue which increased 7.49% to Rs 1,880 crore in FY24. Its other segment 99acres saw a 23.6% growth to Rs 351 crore in FY24. Jeevansathi and Shiksha combined participated with Rs 305 crore of revenue during FY24. Info Edge made Rs 414 crore from non-operating activities tallying its total revenue to Rs 2,950 crore in FY24. Akin to other internet companies, its employee benefits accounted for 61% of its total expenditure which grew only 2.83% to Rs 1,128 crore in FY24 from Rs 1,097 crore in FY22. Info Edge’s network/internet, advertising cum promotional, legal, traveling and other overheads push the total expenditure to Rs 1830 crore in FY23 from Rs 1,858 crore in FY23. Note 1: The company recorded exceptional items of Rs 110 crore and Rs 509 crore in FY24 and FY23 respectively due to the decrease in the carrying value of investments. This was the primary reason for the significant loss posted in FY23. Note 2: The company has 15 joint ventures including Makesense, Happily Unmarried’s Ustraa (now acquired by VLCC), Shopkirana, Juno, Sploot and others during FY24. Info Edge recorded a share loss of Rs 131 crore and 231 crore in FY24 and FY23 respectively in its joint ventures which also makes a part of its consolidated figures and reflects losses in the financial statements. At the end, Indo Edge posted a net profit of Rs 594 crore in FY24 where the figures stood at a loss of Rs 70 crore in FY23 (refer note 1 and 2). On a unit level, it spent Rs 0.72 to earn a rupee in FY23.

Info Edge posts Rs 722 Cr revenue in Q3 FY25; profit jumps 2.5X

EntrackrEntrackr · 5m ago
Info Edge posts Rs 722 Cr revenue in Q3 FY25; profit jumps 2.5X
Medial

Info Edge posts Rs 722 Cr revenue in Q3 FY25; profit jumps 2.5X Info Edge, the parent company of Naukri and 99acres, released its unaudited financial results for Q3 FY25. According to the company’s update sourced from the National Stock Exchange (NSE), revenue from operations grew by 15.2% to Rs 722 crore in Q3 FY25 from Rs 627 crore in Q3 FY24. The company recorded Rs 2,100 crore in revenue during the first nine months of FY25, with profits reaching Rs 632 crore. Info Edge derives the majority of its revenue—73%—from Naukri.com, which contributed Rs 527 crore in Q3 FY25, marking a 12.3% year-on-year growth compared to Q3 FY24. Meanwhile, revenue from 99 acres reached Rs 104 crore, while the Jeevansathi and Shiksha segments collectively generated Rs 91 crore during the same quarter. The company added another Rs 187 crore from interest on deposits and investments, which pushed its overall revenue to Rs 9,094 crore in Q3 FY25, compared to Rs 660 crore in Q3 FY24. Info Edge spent 62.6% of its overall expenditure on employee benefits, which increased by a modest 9.7% year-on-year to Rs 305 crore in Q3 FY25. Its advertising and internet costs stood at Rs 82 crore and 20 crore, respectively. The company’s overall cost grew 7% YoY to Rs 487 crore in Q3 FY25 from Rs 455 crore in Q3 FY24. The steady growth and surge in other income with controlled expenditure led its profits to increase by 142% to Rs 288 crore in Q3 FY25, compared to Rs 119 crore in Q3 FY24. On a unit level, it spent Rs 0.67 to earn a rupee in Q3 FY25. As of 4:40 PM, Info Edge is trading at Rs 7,910, reflecting a Rs 203.1 increase following today's results. Its total market capitalization value improved to Rs 1,02,501 crore ($12.2 billion).

FabHotels gross revenue crosses Rs 550 Cr in FY24, losses widen 23%

EntrackrEntrackr · 5m ago
FabHotels gross revenue crosses Rs 550 Cr in FY24, losses widen 23%
Medial

FabHotels gross revenue crosses Rs 550 Cr in FY24, losses widen 23% Casa2 Stays, the parent firm of FabHotels, reported a 34% increase in gross revenue for the fiscal year ending March 2024. However, its loss rose by 23%, driven by a twofold increase in employee benefit expenses. FabHotels’ gross revenue increased to Rs 552 crore in FY24 from Rs 412 crore in the previous fiscal year (FY23), according to its financial statement sourced from the Registrar of Companies (RoC). The revenue for FY23 appears different this year as it marks FabHotels’ first set of financial statements prepared in compliance with Indian Accounting Standards (Ind AS). FabHotels, a budget hotel chain with over 600 properties across more than 50 cities in India, generated 99.4% of its gross revenue from accommodation bookings. Gross revenue increased by 33.35% to Rs 549 crore in FY24. Meanwhile, other revenue sources contributed Rs 3.3 crore. The company also recorded an additional income of Rs 11 crore from interest on deposits and liabilities written off, which pushed its overall revenue to Rs 563.6 crore in the last fiscal year. Accommodation expenses remained the largest cost component forming 74% of the overall cost, which grew by 32% to Rs 435 crore. FabHotels’ employee costs shot up 2X to Rs 92 crore in FY24. This includes Rs 15 crore as ESOP cost. Its commission expenses rose by 8% to Rs 27 crore, while other costs added Rs 34 crore. Overall, total expenses grew by 38.5% to Rs 588 crore in FY24 from Rs 424.7 crore in FY23. The two-fold jump in employee benefits led FabHotel to increase its losses by 23% to Rs 114 crore in FY24, compared to Rs 93 crore in FY23. Its ROCE and EBITDA Margin were recorded at -84.09% and -19.52%, respectively. On a unit basis, the company spent Rs 1.06 to earn a rupee of revenue. At the end of FY24, FabHotel’s current assets stood at Rs 172 crore, including cash and bank balances worth Rs 94 crore. FabHotel has raised around $70 million to date. Accel is the largest external stakeholder with 21.39% followed by Goldman Sachs. FabHotels competes directly with Treebo and Bloom Hotels. In FY24, Treebo surpassed Rs 100 crore in revenue, while Bloom Hotels achieved a 73.6% increase in operational revenue to Rs 250 crore and recorded a profit of Rs 14 crore. FabHotels, with its budget offerings and reach, faces a moment of truth to deliver sustainable profitability that can power future growth. The hospitality sector leaves very little margin for major misses now. FabHotels has placed its bets, with little leeway to change much now. Judgement awaits in the next few months and year, perhaps.

Info Edge posts Rs 750 Cr revenue in Q4 FY25; profit jumps 7.7X

EntrackrEntrackr · 1m ago
Info Edge posts Rs 750 Cr revenue in Q4 FY25; profit jumps 7.7X
Medial

Info Edge, the parent company of Naukri and 99acres, reported a 14.2% growth in operating revenue in the fourth quarter of the last fiscal year (FY25), while its profit jumped 7.7X due to a decline in expenses. The Noida-based company’s operating revenue rose to Rs 750 crore in Q4 FY25 from Rs 657 crore in Q4 FY24, according to documents sourced from the National Stock Exchange (NSE). On a fiscal basis, the Sanjeev Bikhchandani-led firm recorded Rs 2,849 crore in revenue during FY25, a 12% increase from Rs 2,536 crore in FY24. Info Edge derives the majority of its revenue from Naukri.com, which contributed Rs 542 crore in the quarter ending March 2025, a 13% year-on-year growth compared to Q4 FY24. Meanwhile, revenue from 99acres reached Rs 106 crore, while the Jeevansathi and Shiksha segments collectively generated Rs 102 crore during the same quarter. The company added another Rs 520 crore from interest on deposits and investment which pushed its overall revenue to Rs 1,270 crore in Q4 FY25. On the fiscal basis, its total income stood at Rs 3,922 crore in FY25. On expense side, Info Edge spent 61% of its overall expenditure on employee benefits, which increased a modest 13% year-on-year to Rs 331 crore in Q4 FY25. Its advertising and internet costs stood at Rs 100 crore and 21 crore, respectively. The company’s overall cost grew 15% YoY to Rs 539 crore in Q4 FY25 from Rs 469 crore in Q4 FY24. Meanwhile on the fiscal basis, total cost rose 9% to Rs 2,002 crore in FY25. The steady growth and surge in other income with controlled expenditure led its profits to spike 7.7X to Rs 678 crore in Q4 FY25, compared to Rs 88 crore in Q4 FY24. On a fiscal basis, the firm’s profit doubled to Rs 1,310 crore in FY25 from Rs 594 crore in FY24. As of 2:43 PM, Info Edge is trading at Rs 1,456, down 1.19% from today’s opening price. The firm’s market capitalization stands at Rs 94,337 crore.

Truemeds to raise $44 Mn led by Accel India

EntrackrEntrackr · 4m ago
Truemeds to raise $44 Mn led by Accel India
Medial

Telehealth platform Truemeds is raising Rs 375.2 crore or (approximately $44 million) in its Series C round led by Accel India and with the participation of WestBridge and Info Edge. The board at Telehealth platform Truemeds has passed a special resolution to issue 1 equity and 49,300 Series C preference shares at an issue price of Rs 76,110 each to raise the aforementioned sum, its regulatory filing accessed from the Registrar of Companies (RoC) shows. Accel India will invest Rs 285.4 crore, while WestBridge, through its investment vehicles Konark and MMPL Trust, will contribute Rs 68.49 crore. Info Edge will also join the round with Rs 21.31 crore. The company will use these proceeds to advance the business and facilitate the planned growth, as per filings. According to Entrackr’s estimates, the company will be valued at around $340 million (post-money). With the new funding, Accel India will hold approximately 10% of the company, while WestBridge and Info Edge will own 28.64% and 23.02%, respectively. Co-founders Akshat Nayyar and Kunal Wani will collectively retain a 22.43% stake in their personal capacity. Founded by Nayyar and Wani, Truemeds lets consumers find medicines of alternate brands with the help of prescriptions uploaded by them. Truemeds recorded an impressive two-fold growth in its revenue to Rs 315 crore during the fiscal year ended March 2024. Efficient cost management and scaling efforts also contributed to a 9% reduction in losses, bringing them down to Rs 61 crore during the same period. Awareness of generic medicines has been rising fast in India, thanks to government-backed efforts to provide cheaper meds at both state and central levels. While that has created a market for users looking beyond the prescribed options, it also brings with it the biggest challenge for Truemeds. Truly successful government efforts will undermine growth in quite a few of the high-volume categories. However, with government efforts focused on select, high-usage molecules, it leaves enough potential for firms like Truemeds to capitalize on the new awareness for options. That seems to be the thesis of the latest funding at least. Be it vitamins and supplements, or even Homeopathic meds, the firm has built up a wide selection on offer for users seeking cheaper options here. Competition remains intense, however, both from government-backed pharmacies or private pharmacies that have also latched on to the new reality of a changing market.

Exclusive: Peak XV joins Truemeds’ Series C round with $20 Mn

EntrackrEntrackr · 1d ago
Exclusive: Peak XV joins Truemeds’ Series C round with $20 Mn
Medial

Exclusive: Peak XV joins Truemeds’ Series C round with $20 Mn Telehealth platform Truemeds has secured another $20 million or Rs 174.33 crore in its ongoing Series C round from new investor Peak XV Partners. This investment is an extension of the $44 million raised by Truemeds in March this year, led by Accel, which was exclusively reported by Entrackr. The board at Truemeds has allotted 19,737 Series C2 compulsory convertible preference shares at an issue price of Rs 88,331 each to raise the aforementioned sum from Peak XV, its regulatory filing accessed from the Registrar of Companies (RoC) shows. The company plans to utilise the funds for business expansion and to support its growth plans, according to the filing. As per Entrackr’s estimates, its valuation stood at $410 million (Rs 3,487 crore) in the new tranche (post-allotment), a 22% increase from its C1 tranche. Founded by Naitik Nayyar and Akshat Wani, Truemeds helps consumers discover cost-effective alternative brands for prescribed medicines by analyzing the prescriptions they upload. It partners with certified pharmacies to deliver medicines at discounted prices, aiming to make healthcare more affordable and accessible. According to startup data intelligence platform TheKredible, the firm has raised over $90 million to date. Following the latest allotment, Peak XV holds a 5% stake in the company. Westbridge is the largest shareholder in Truemeds followed by Info Edge which owns 21.87% stake. Co-founders Naitik Nayyar and Akshat Wani both collectively retain 21.3%. Truemeds doubled its revenue to Rs 315 crore in FY24, while its losses narrowed by 9% to Rs 61 crore during the same period. The Mumbai-based firm competes with telehealth platforms like PharmEasy, which recorded Rs 5,664 crore in revenue in FY24, and Tata 1mg, which posted Rs 1,964 crore.

Download the medial app to read full posts, comements and news.